BTIG Research Upgrades Innate Pharma (NASDAQ:IPHA) to Strong-Buy

Innate Pharma (NASDAQ:IPHA) was upgraded by research analysts at BTIG Research to a “strong-buy” rating in a report issued on Wednesday,Zacks.com reports.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Innate Pharma in a report on Thursday, January 22nd. Two investment analysts have rated the stock with a Strong Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Innate Pharma has an average rating of “Moderate Buy” and an average price target of $5.00.

Innate Pharma Price Performance

NASDAQ:IPHA opened at $1.50 on Wednesday. Innate Pharma has a twelve month low of $1.40 and a twelve month high of $2.63. The company’s 50-day moving average price is $1.71 and its 200-day moving average price is $1.86.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of IPHA. Jane Street Group LLC purchased a new stake in shares of Innate Pharma in the 4th quarter valued at $162,000. OLD Mission Capital LLC purchased a new position in shares of Innate Pharma in the fourth quarter valued at approximately $50,000. Finally, Millennium Management LLC acquired a new position in shares of Innate Pharma in the fourth quarter valued at approximately $36,000. 0.16% of the stock is currently owned by hedge funds and other institutional investors.

Innate Pharma Company Profile

Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body’s innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.

The company’s lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.